Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: HIV Infections
Interventions: Kaletra® (lopinavir/ritonavir), Combivir® (lamivudine, zidovudine), Sustiva® (efavirenz); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: HIV Infections
Interventions: GW695634; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 18
States / cities: Phoenix, Arizona • Fountain Valley, California • San Francisco, California + 15 more

Conditions: Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions: There is no intervention in this study; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Hepatitis C, Chronic
Interventions: BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 31
States / cities: North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer
Interventions: DETEC® Esterase; Diagnostic Test
Lead sponsor: Progenitec Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Surgical Site Infection
Interventions: Mepilex Border Post-Op Ag, Standard Postoperative Dressing; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: TRUVADA + Raltegravir; Drug
Lead sponsor: Fenway Community Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Zidovudine, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 13 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 23
States / cities: Concord, California • Long Beach, California • Orlando, Florida + 15 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Placebo Administration, Stem Cell Mobilization Therapy; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts

Conditions: Wounds, Hidradenitis Suppurativa, Hidradenitis, Acne Inversa
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Amphotericin B; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Jose, California + 18 more

Conditions: HIV Infections, Chickenpox
Interventions: Sorivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: HIV Infections
Interventions: HST-NEETs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions: Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 11
States / cities: Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: HIV-1-infection
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC); Drug
Lead sponsor: The Crofoot Research Center, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Fort Lauderdale, Florida

Conditions: HIV Infections, Hepatitis B
Interventions: Enhanced HIV risk reduction and HIV vaccine education; Behavioral
Lead sponsor: New York Blood Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Chronic Mental Illness, Chronic Physical Illness
Interventions: Patient-Directed Wellness Account, Health Navigator; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 55 Years
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hepatitis C, HIV
Interventions: boceprevir; etravirine; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Gut Microbiome, Gastrointestinal Microbiome, COVID, COVID-19, Corona Virus Infection, Coronavirus, Coronaviridae Infections, Coronavirus 19, Coronavirus-19, COVID 19
Interventions: There is no intervention in this study; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Ventura, California

Conditions: Non-infectious Uveitis
Interventions: Basiliximab, Placebo; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Cambridge, Massachusetts • Kansas City, Missouri • New York, New York + 3 more

Conditions: RSV Infection
Interventions: EDP-938, Itraconazole, Rifampin, Quinidine; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Hepatitis C
Interventions: Polyenylphosphatidylcholine (PPC), Pegylated Interferon, Ribavirin; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 67 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects

Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

DETEC® Esterase for Screening Wound Infection at Point of Care

The Mepilex Cesarean Delivery Trial / MEPIDEL

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Wound Etiology and Healing Study

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Project UNITY - HIV Risk Reduction and Vaccine Education Interventions

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

A Study to Explore the Role of Gut Flora in COVID-19 Infection

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers